BR112022007929A2 - Purificação de proteínas - Google Patents

Purificação de proteínas

Info

Publication number
BR112022007929A2
BR112022007929A2 BR112022007929A BR112022007929A BR112022007929A2 BR 112022007929 A2 BR112022007929 A2 BR 112022007929A2 BR 112022007929 A BR112022007929 A BR 112022007929A BR 112022007929 A BR112022007929 A BR 112022007929A BR 112022007929 A2 BR112022007929 A2 BR 112022007929A2
Authority
BR
Brazil
Prior art keywords
protein purification
purifying
protein
biotherapeutics
vaccines
Prior art date
Application number
BR112022007929A
Other languages
English (en)
Inventor
Polilli Brian
Rode Christopher
Schreffler John
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of BR112022007929A2 publication Critical patent/BR112022007929A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PURIFICAÇÃO DE PROTEÍNAS. A presente invenção refere-se a um processo para a purificação de proteínas, em particular um processo para a purificação de uma glicoproteína, tal como uma proteína do envelope do HIV, útil para vacinas ou bioterápicos.
BR112022007929A 2019-11-07 2020-11-06 Purificação de proteínas BR112022007929A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932180P 2019-11-07 2019-11-07
US202063105664P 2020-10-26 2020-10-26
PCT/EP2020/081271 WO2021089770A2 (en) 2019-11-07 2020-11-06 Protein purification

Publications (1)

Publication Number Publication Date
BR112022007929A2 true BR112022007929A2 (pt) 2022-07-12

Family

ID=73198294

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007929A BR112022007929A2 (pt) 2019-11-07 2020-11-06 Purificação de proteínas

Country Status (11)

Country Link
US (1) US11857619B2 (pt)
EP (1) EP4054629A2 (pt)
JP (1) JP7170942B1 (pt)
KR (1) KR20220092896A (pt)
CN (1) CN114585639A (pt)
AU (1) AU2020381082B2 (pt)
BR (1) BR112022007929A2 (pt)
CA (1) CA3159907A1 (pt)
IL (1) IL292760A (pt)
MX (1) MX2022005502A (pt)
WO (1) WO2021089770A2 (pt)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297604A1 (en) * 2006-06-09 2010-11-25 Xing-Xiang Li Methods and reagents for virus isolation and detection
EP2040746A4 (en) 2006-06-19 2009-12-16 Progenics Pharm Inc METHODS OF RECOVERING STABILIZED FORMULATIONS OF RETROVIRAL ENVELOPE (ENV) PROTEIN TRIMERS
PT3335728T (pt) 2008-10-10 2020-02-19 Childrens Medical Center Vacina de trímero de envelope para hiv-1 bioquimicamente estabilizada
JP5814951B2 (ja) * 2010-03-10 2015-11-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 免疫グロブリン溶液を精製するための方法
SG11201505229XA (en) 2013-01-07 2015-08-28 Beth Israel Hospital Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
US10144774B2 (en) * 2013-07-01 2018-12-04 Csl Behring Ag Method for purifying IgG
US10526583B2 (en) * 2014-07-02 2020-01-07 University Of Florida Research Foundation, Incorporated Compositions and methods for purifying recombinant adeno-associated virus
ES2865150T3 (es) 2014-09-26 2021-10-15 Beth Israel Deaconess Medical Ct Inc Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana
US10738078B2 (en) * 2014-11-03 2020-08-11 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
JP6510149B2 (ja) 2015-12-15 2019-05-08 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法
MX2018013455A (es) * 2016-05-02 2019-02-28 Scripps Research Inst Composiciones y metodos relacionados con inmunogenos de vih-1.
KR102389489B1 (ko) 2016-06-16 2022-04-22 얀센 백신스 앤드 프리벤션 비.브이. Hiv 백신 제형
SG11202000112XA (en) * 2017-07-19 2020-02-27 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
US20220041650A1 (en) * 2018-12-03 2022-02-10 Duke University Purification method for recombinant proteins and nanoparticles

Also Published As

Publication number Publication date
AU2020381082B2 (en) 2022-09-22
US11857619B2 (en) 2024-01-02
IL292760A (en) 2022-07-01
JP2022547341A (ja) 2022-11-11
MX2022005502A (es) 2022-06-02
CA3159907A1 (en) 2021-05-14
WO2021089770A3 (en) 2021-07-01
WO2021089770A2 (en) 2021-05-14
US20210138060A1 (en) 2021-05-13
CN114585639A (zh) 2022-06-03
JP7170942B1 (ja) 2022-11-14
KR20220092896A (ko) 2022-07-04
AU2020381082A1 (en) 2022-04-28
EP4054629A2 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
CL2018002825A1 (es) Vacuna contra vrs
BR112019002357A2 (pt) purificação de matéria-prima por tratamento térmico
MD3445850T2 (ro) Metode de obținere a ARN monocatenar
CO2018002196A2 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
BR112016029318A2 (pt) tratamento de mielomas
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
BR112013006384A2 (pt) processo para produção de fibrinogênio
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
WO2018162557A3 (en) Method for purifying proteins using silicate
BR112019005886A2 (pt) tratamento com água de material lipídico
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
EA201890710A1 (ru) Способ очистки гидролизата биомассы
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
BR112017001177A2 (pt) processo para a purificação de poliovírus a partir de culturas celulares
CL2018000164A1 (es) Vector recombinante del virus orf.
CL2020002597A1 (es) Métodos para preparar composiciones proteicas estables
MX2017009812A (es) Composiciones y metodos para inhibir infeccion viral.
BR112018011085A2 (pt) composições farmacêuticas contendo doravirina, fumarato de tenofovir desoproxila e lamivudina
BR112017016110A2 (pt) composições de imunoglobulina equina e usos para tratamento de doenças mediadas por filovírus
GB2544439A (en) Antiviral composition
BR112022007929A2 (pt) Purificação de proteínas
BR112017009503A2 (pt) composição farmacêutica parenteral de ação prolongada, métodos para tratar, para prevenir e para curar uma infecção por hcv, e, kit.
MX2015010763A (es) Proteinas h5 del virus de la gripe h5n1 para uso como un medicamento.
BR112015023591A2 (pt) processo para a preparação de 4-amino-1-((ls,4r,5s)-2-fluoro-4,5-di-hidróxi-3-hidroximetil-ciclopent-2-enii)-1h-pirimidin-2-ona

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]